These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32710539)

  • 1. Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson's Disease.
    Redenšek S; Jenko Bizjan B; Trošt M; Dolžan V
    Int J Neuropsychopharmacol; 2020 Nov; 23(8):496-504. PubMed ID: 32710539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease.
    Kraemmer J; Smith K; Weintraub D; Guillemot V; Nalls MA; Cormier-Dequaire F; Moszer I; Brice A; Singleton AB; Corvol JC
    J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1106-11. PubMed ID: 27076492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical-Pharmacogenetic Predictive Models for Time to Occurrence of Levodopa Related Motor Complications in Parkinson's Disease.
    Redenšek S; Jenko Bizjan B; Trošt M; Dolžan V
    Front Genet; 2019; 10():461. PubMed ID: 31156712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson's Disease.
    Damasceno Dos Santos EU; Duarte EBC; Miranda LMR; Asano AGC; Asano NMJ; Maia MMD; de Souza PRE
    J Clin Pharmacol; 2019 Jul; 59(7):1006-1013. PubMed ID: 30794329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease.
    Redenšek S; Flisar D; Kojović M; Kramberger MG; Georgiev D; Pirtošek Z; Trošt M; Dolžan V
    J Neuroinflammation; 2019 Feb; 16(1):50. PubMed ID: 30813952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder.
    Drew DS; Muhammed K; Baig F; Kelly M; Saleh Y; Sarangmat N; Okai D; Hu M; Manohar S; Husain M
    Brain; 2020 Aug; 143(8):2502-2518. PubMed ID: 32761061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease.
    Redenšek S; Flisar D; Kojović M; Gregorič Kramberger M; Georgiev D; Pirtošek Z; Trošt M; Dolžan V
    Front Pharmacol; 2019; 10():8. PubMed ID: 30745869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs.
    Poletti M; Logi C; Lucetti C; Del Dotto P; Baldacci F; Vergallo A; Ulivi M; Del Sarto S; Rossi G; Ceravolo R; Bonuccelli U
    J Clin Psychopharmacol; 2013 Oct; 33(5):691-4. PubMed ID: 23857310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study.
    Biundo R; Weis L; Abbruzzese G; Calandra-Buonaura G; Cortelli P; Jori MC; Lopiano L; Marconi R; Matinella A; Morgante F; Nicoletti A; Tamburini T; Tinazzi M; Zappia M; Vorovenci RJ; Antonini A
    Mov Disord; 2017 Nov; 32(11):1557-1565. PubMed ID: 28960475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients.
    Krishnamoorthy S; Rajan R; Banerjee M; Kumar H; Sarma G; Krishnan S; Sarma S; Kishore A
    Parkinsonism Relat Disord; 2016 Sep; 30():13-7. PubMed ID: 27325396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias.
    Hinkle JT; Perepezko K; Rosenthal LS; Mills KA; Pantelyat A; Mari Z; Tochen L; Bang JY; Gudavalli M; Yoritomo N; Butala A; Bakker CC; Johnson V; Moukheiber E; Dawson TM; Pontone GM
    Parkinsonism Relat Disord; 2018 Feb; 47():50-56. PubMed ID: 29198499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hallucinations in Parkinson's disease].
    Moser A; Hagenah J; Kömpf D
    Nervenarzt; 2003 Apr; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing impulse control behaviours in Parkinson's disease: practical guidelines.
    Macphee GJ; Chaudhuri KR; David AS; Worth P; Wood B
    Br J Hosp Med (Lond); 2013 Mar; 74(3):160-6. PubMed ID: 23665786
    [No Abstract]   [Full Text] [Related]  

  • 14. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease.
    Makoff AJ; Graham JM; Arranz MJ; Forsyth J; Li T; Aitchison KJ; Shaikh S; Grünewald RA
    Pharmacogenetics; 2000 Feb; 10(1):43-8. PubMed ID: 10739171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The high prevalence of impulse control behaviors in patients with early-onset Parkinson's disease: A cross-sectional multicenter study.
    Vela L; Martínez Castrillo JC; García Ruiz P; Gasca-Salas C; Macías Macías Y; Pérez Fernández E; Ybot I; Lopez Valdés E; Kurtis MM; Posada Rodriguez IJ; Mata M; Ruiz Huete C; Eimil M; Borrue C; Del Val J; López-Manzanares L; Rojo Sebastian A; Marasescu R
    J Neurol Sci; 2016 Sep; 368():150-4. PubMed ID: 27538621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impulse control symptoms in patients with Parkinson's disease: The influence of dopaminergic agonist.
    Vargas AP; Vaz LS; Reuter A; Couto CM; Costa Cardoso FE
    Parkinsonism Relat Disord; 2019 Nov; 68():17-21. PubMed ID: 31621612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.
    Politi C; Ciccacci C; Novelli G; Borgiani P
    Neuromolecular Med; 2018 Mar; 20(1):1-17. PubMed ID: 29305687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does response inhibition have pre- and postdiagnostic utility in Parkinson's disease?
    MacDonald HJ; Byblow WD
    J Mot Behav; 2015; 47(1):29-45. PubMed ID: 25575221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
    Moreau C; Meguig S; Corvol JC; Labreuche J; Vasseur F; Duhamel A; Delval A; Bardyn T; Devedjian JC; Rouaix N; Petyt G; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Azulay JP; Tison F; Destée A; Vidailhet M; Rascol O; Dujardin K; Defebvre L; Bordet R; Sablonnière B; Devos D;
    Brain; 2015 May; 138(Pt 5):1271-83. PubMed ID: 25805645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants.
    Castro-Martínez XH; García-Ruiz PJ; Martínez-García C; Martínez-Castrillo JC; Vela L; Mata M; Martínez-Torres I; Feliz-Feliz C; Palau F; Hoenicka J
    Parkinsonism Relat Disord; 2018 Apr; 49():100-103. PubMed ID: 29361389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.